Liquidia (NASDAQ:LQDA) Director Sells $9,603,972.76 in Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 148,301 shares of the firm’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $64.76, for a total transaction of $9,603,972.76. Following the transaction, the director owned 1,636,941 shares of the company’s stock, valued at approximately $106,008,299.16. This represents a 8.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Liquidia Stock Down 0.6%

Shares of LQDA opened at $71.23 on Friday. The stock has a market cap of $6.33 billion, a price-to-earnings ratio of 508.82 and a beta of 0.58. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a 12 month low of $11.85 and a 12 month high of $72.71. The company has a 50-day moving average price of $49.85 and a two-hundred day moving average price of $40.89.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. The firm had revenue of $132.87 million during the quarter, compared to analysts’ expectations of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The company’s quarterly revenue was up 4187.1% on a year-over-year basis. Equities analysts predict that Liquidia Corporation will post 2.97 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of LQDA. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Liquidia in the 4th quarter worth approximately $25,000. NewEdge Advisors LLC acquired a new position in shares of Liquidia in the 2nd quarter worth approximately $25,000. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Liquidia in the 3rd quarter worth approximately $30,000. FNY Investment Advisers LLC bought a new position in Liquidia in the 3rd quarter worth approximately $34,000. Finally, Covestor Ltd raised its position in Liquidia by 41.9% in the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after purchasing an additional 359 shares during the last quarter. 64.54% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have commented on LQDA shares. Raymond James Financial restated a “strong-buy” rating and set a $68.00 price target on shares of Liquidia in a research note on Thursday, June 4th. BTIG Research lifted their target price on shares of Liquidia from $50.00 to $59.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Wells Fargo & Company boosted their target price on Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. Needham & Company LLC boosted their target price on Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a report on Tuesday, April 21st. Three analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $60.29.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).